Shots:

• The P-ll study involves assessing of ATYR1923 (1.0 & 3.0 mg/kg) vs PBO in 32 hospitalized COVID-19 patients in the ratio of (1:1:1) with severe respiratory complications who do not require mechanical ventilation in the US and Puerto Rico
• Result: the study met its 1EPs of safety- demonstrating that ATYR1923 (single dose- IV) was safe and well-tolerated in both treatment groups- with no SAEs- median time to recovery @3.0 mg/kg dose (5.5 vs 6 days); recovery by day 6 (83% vs 56%); median time to recovery @1.0 mg/kg dose (7days)
• The company is developing the therapy for patients with inflammatory lung diseases

 ­ Ref: Atyr Pharma | Image: American College of Cardiology